Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 16/20 | 0.36 |
| ▸ | GSK3B | P49841 | 4/20 | 0.36 |
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | GRK6 | P43250 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2148867 | 0.89 | AURKA (0.47) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2169274 | 0.84 | AURKB (0.47) | AURKAAURKBGSK3BSRCAURKC | |
| SCHEMBL2149092 | 0.82 | AURKA (0.32) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2148630 | 0.82 | AURKA (0.32) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2153217 | 0.81 | SRC (0.44) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2203289 | 0.80 | AURKA (0.47) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2169069 | 0.79 | GRK6 (0.39) | AURKANTRK1GRK6 | |
| SCHEMBL2159843 | 0.77 | AURKA (0.43) | AURKAAURKBGSK3BSRCNTRK1 | |
| SCHEMBL2149892 | 0.76 | AURKA (0.61) | AURKAAURKBAURKC | |
| SCHEMBL2948567 | 0.75 | AURKB (0.64) | AURKAAURKBGSK3BSRCAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011088045-A1 | AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE | AMBIT BIOSCIENCES CORPORATION (US) | 2011-07-21 | — | — | WO | disclosed |